| Prev Close | 32.91 |
| Day Low/High | 32.54 / 33.29 |
| 52 Wk Low/High | 22.64 / 34.05 |
Taylor Morrison Home Corporation (TMHC)
32.83
NYSE
| Exchange | NYSE |
| Shares Outstanding | 122.89B |
| Market Cap | 4.04B |
| P/E Ratio | 18.18 |
| Div & Yield | N.A. (N.A) |
Latest News
Taylor Morrison Homes Could Be Move-In Ready on a Breakout
Charts and indicators for the homebuilder are constructive.
4 Financial Names That Offer Value in a Market Where It's Tough to Find
These companies are trading at reasonable multiples and two are offering nice dividend yields, too.
Homebuilder Lennar Is Poised for an Upside Breakout
I feel good in recommending the long side of LEN at current levels.
Exodus From Big Cities Spells Opportunity in Several Names
Furniture sellers, homebuilders and home improvement and décor retailers should benefit as people establish new digs outside urban areas.
Opportunity Keeps Knocking as Markets Ignore Covid-19 and Social Unrest
Some stocks have rebounded far more than expected while others appear to be getting back into gear.
Taylor Morrison Home Can Build Off Recent Gains
Here's how to trade shares of the nation's fifth largest homebuilder.
I Still Like Housing, Just Not as Much as Before
After the strong run of homebuilders in 2019, the sector simply isn't as oversold as it was to start the year.
6 Ways to Build Value With Homebuilding Stocks
Low interest rates, continued low unemployment and high consumer confidence are bullish props to this sector.
I'm Unapologetically Overweight in These 2 Sectors
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
Taylor Morrison Home Is Building Toward New Highs
Here's how we would play this homebuilder
3 Small-Cap Names in the Red-Hot Housing Sector That Are Worth a Look
Beazer Homes USA, Taylor Morrison Home Corp. and Hooker Furniture is a trio to consider.
These 5 Small Caps Are Well Positioned Despite Escalating Trade Tensions
They're the kind of names, along with a big dollop of cash in my portfolio, I plan to wait out the 'trade wars'.
These Homebuilders Have Curb Appeal
The housing market should post much stronger performance in the second half of the year, provided the jobs market remains solid. Here's how to play it.
Checking Back With 3 Smaller Homebuilders
I do think consolidation across this very fragmented industry will pick up in the quarters ahead.
Big Dips Means Adding to My Holdings
Achaogen, Taylor Morrison and Synchrony Financial are a part of my current shopping list.
Homebuilders Set to Raise Roof on Tax Plan
Legislation should provide a powerful earnings boost for the industry and these names.
These Stocks Are Ready to Reverse Course
This week's bullish and bearish reversal patterns.
Housing is Becoming a Battleground Sector
The market continues to be slightly positive in a day that has seen little movement in the major indices since the open. It seems housing is becoming a battleground sector among analysts lately. Barclays downgraded myriad homebuilders after recent r...
I'm Still Sold on Homebuilders
Smaller builders are of particular interest because they're acquisition candidates in a fragmented market.
Halfway Point Points to Biotech, Housing
The two sectors hold more promise than most in the back half of 2017.
Infrastructure Has a Shaky Foundation
But home builders continue to construct a strong story.
Infrastructure Has a Shaky Foundation
But home builders continue to construct a strong story.
Small Homebuilders Are Tempting
Homebuilders are the second-largest allocation within my biotech.
Early-Morning Earnings Extravaganza
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Smaller Homebuilders Are Looking Attractive
They have faster growth prospects and sell for slightly cheaper valuations, as well.
I'm Big on Housing Entering Quarter No. 2
Home builders make up the second-largest allocation in my portfolio, behind biotech.
Sharp Ideas from U of M's Value 40 Fund
This is a great shopping list of undervalued stocks with the potential for big long-term returns.
